These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10233199)

  • 1. A pharmacokinetic model for alpha interferon administered subcutaneously.
    Chatelut E; Rostaing L; Grégoire N; Payen JL; Pujol A; Izopet J; Houin G; Canal P
    Br J Clin Pharmacol; 1999 Apr; 47(4):365-71. PubMed ID: 10233199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.
    Rostaing L; Chatelut E; Payen JL; Izopet J; Thalamas C; Ton-That H; Pascal JP; Durand D; Canal P
    J Am Soc Nephrol; 1998 Dec; 9(12):2344-8. PubMed ID: 9848789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C.
    Xu C; Gupta S; Krishna G; Cutler D; Wirth S; Galoppo C; Ciocca M; Kolz K; Noviello S; Sniukiene V
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2045-54. PubMed ID: 23975236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
    Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
    Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.
    Jen JF; Glue P; Ezzet F; Chung C; Gupta SK; Jacobs S; Hajian G
    Clin Pharmacol Ther; 2001 Jun; 69(6):407-21. PubMed ID: 11406738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.
    Daud AI; Xu C; Hwu WJ; Urbas P; Andrews S; Papadopoulos NE; Floren LC; Yver A; Deconti RC; Sondak VK
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):657-66. PubMed ID: 20509027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
    Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
    Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers.
    Serra DB; Sun H; Karwowska S; Praestgaard J; Halabi A; Stein DS
    Antimicrob Agents Chemother; 2011 Feb; 55(2):473-7. PubMed ID: 21098255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.
    Fruit D; Rousseau A; Amrein C; Rollé F; Kamar N; Sebbag L; Redonnet M; Epailly E; Marquet P; Prémaud A
    Clin Pharmacokinet; 2013 Apr; 52(4):277-88. PubMed ID: 23400901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
    Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
    Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients.
    Saleh MI
    Clin Pharmacokinet; 2017 Nov; 56(11):1369-1379. PubMed ID: 28397081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.
    Gupta SK; Pittenger AL; Swan SK; Marbury TC; Tobillo E; Batra V; Sack M; Glue P; Jacobs S; Affrime M
    J Clin Pharmacol; 2002 Oct; 42(10):1109-15. PubMed ID: 12362925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.